|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
1R44CA221539-01
|
$1,206,955
|
$1,206,955
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
MOTILITY AND INVASION
|
5P01CA100324-15
|
$2,028,990
|
$202,899
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$966,144
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
$138,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-03
|
$473,915
|
$236,958
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
MiRNAs in hepatocellular carcinoma development and treatment
|
2R01CA139158-06A1
|
$410,875
|
$205,438
|
HUANG, WENDONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas
|
5R01CA198076-03
|
$1
|
$1
|
PORTNOW, JANA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-04
|
$312,304
|
$156,152
|
ZAIA, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
$276,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Image-guided EMT inhibition for treating metastatic breast cancer
|
5R01CA194518-03
|
$473,853
|
$156,371
|
LU, ZHENG-RONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Genetic Toolbox for the Identification and Interrogation of Tumor Cells of Origin, Propagation, and Recurrence From Patient-derived Oncogenic Drivers
|
5R33CA202900-02
|
$412,553
|
$412,553
|
BREUNIG, JOSHUA
|
CEDARS-SINAI MEDICAL CENTER
|
|
DICER1 and the Pleuropulmonary Blastoma Family Cancer Syndrome
|
5R01CA143167-07
|
$407,577
|
$407,577
|
HILL, DANA
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5R00CA172292-05
|
$248,999
|
$74,700
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
CRLF2 signaling in B-cell acute lymphoblastic leukemia
|
5R01CA151898-07
|
$392,969
|
$196,485
|
WEINSTOCK, DAVID
|
DANA-FARBER CANCER INST
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
5R44CA186410-03
|
$998,609
|
$499,305
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Exploring the therapeutic potential and pathogenic contribution of MTAP deletion in Glioblastoma
|
1F30CA206336-01A1
|
$35,090
|
$35,090
|
HANSEN, LANDON
|
DUKE UNIVERSITY
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-04
|
$2,298,025
|
$91,921
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-10
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-17
|
$701,719
|
$231,567
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-09
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
|
1R01CA207407-01A1
|
$371,925
|
$371,925
|
STEPHAN, MATTHIAS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-19
|
$2,023,730
|
$951,153
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinoma
|
5R35CA197452-03
|
$904,402
|
$904,402
|
FLORES, ELSA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Tissue-specific tumor suppressor effects of p53
|
3R01CA200256-03S1
|
$78,178
|
$39,089
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Tissue-specific tumor suppressor effects of p53
|
5R01CA200256-03
|
$432,908
|
$216,454
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Nanoparticle modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer
|
5R01CA195503-02
|
$10,280
|
$10,280
|
GREEN, JORDAN
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
|
5R01CA204968-02
|
$512,053
|
$512,053
|
HANES, JUSTIN
|
JOHNS HOPKINS UNIVERSITY
|
|
Optimal DNA Brain-Penetrating Nanoparticle (DNA-BPN) Formulation for Glioblastoma (GBM) Treatment
|
5F31CA210610-02
|
$44,044
|
$44,044
|
NEGRON, KARINA
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Prostate Cancer
|
5P50CA058236-22
|
$1,993,426
|
$398,685
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-14
|
$2,300,000
|
$299,000
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
5R01CA183040-04
|
$336,150
|
$336,150
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Cancer-targeted local pulmonary immunotherapy with PD-L1 inhibitory peptide secretory genes for the treatment of lung cancer
|
1R15CA219919-01
|
$380,000
|
$380,000
|
TAMURA, MASAAKI
|
KANSAS STATE UNIVERSITY
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-04
|
$778,686
|
$389,343
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-03
|
$49,044
|
$49,044
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells
|
5K22CA197053-03
|
$200,880
|
$200,880
|
BADR, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
|
2P01CA069246-20
|
$1,387,951
|
$610,698
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Optimizing Cancer Immunotherapy Safety and Efficacy using Genome Editing
|
1K99CA218870-01
|
$143,370
|
$143,370
|
KLEINSTIVER, BENJAMIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt Tumor Cell Adhesion and Bone Metastasis Formation In Vivo
|
3F32CA200351-02S1
|
$1,678
|
$1,678
|
MITCHELL, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt Tumor Cell Adhesion and Bone Metastasis Formation In Vivo
|
5F32CA200351-03
|
$57,066
|
$57,066
|
MITCHELL, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Regulatory Pathways and Role of VPF/VEGF in Renal Cancer
|
5R01CA078383-19
|
$334,519
|
$334,519
|
MUKHOPADHYAY, DEBABRATA
|
MAYO CLINIC JACKSONVILLE
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
3R01CA183827-03S1
|
$133,280
|
$133,280
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
7R01CA183827-03
|
$322,194
|
$322,194
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Nanoparticle Modified Human Fat Derived Mesenchymal Stem Cells for Brain Cancer (Change of Organization Application)
|
7R01CA195503-03
|
$364,553
|
$364,553
|
QUINONES-HINOJOSA, ALFREDO
|
MAYO CLINIC JACKSONVILLE
|
|
Molecular Basis of Familial Paraganglioma
|
5R01CA166025-05
|
$296,933
|
$97,988
|
MAHER, LOUIS
|
MAYO CLINIC ROCHESTER
|
|
Mechanism of gp96/grp94 in regulating plasma cells and myeloma
|
5R01CA193939-02
|
$346,350
|
$173,175
|
LIU, BEI
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$936,196
|
$140,429
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immune cell control of ovarian cancer
|
ZIA BC 011775
|
$309,150
|
$61,830
|
Annunziata, Christina
|
CCR (NCI)
|
|
Mechanisms of Chromosome Maintenance in Bacteria
|
ZIA BC 010277
|
$518,152
|
$51,815
|
Chattoraj, Dhruba
|
CCR (NCI)
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,268,391
|
$25,368
|
Cooper, Julia
|
CCR (NCI)
|
|
Lambda Genetic Networks and Lambda Red-Mediated Recombination
|
ZIA BC 010336
|
$1,316,136
|
$329,034
|
Court, Donald
|
CCR (NCI)
|
Total relevant funding to Gene Therapy for this search: $35,689,813
|